Trials / Terminated
TerminatedNCT00667953
Study of Temzolomide and Gleevec in Advanced Melanoma
Phase I/II Study of Temozolomide and Gleevec (Imatinib Mesylate, Formerly Known as STI571) in Advanced Melanoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study has been designed to evaluate the side effects of Gleevec when given in combination with Temzolomide; and to learn more about how these drugs work in the body and whether this combination is useful in treating patients with melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gleevec | Gleevec (600 mg) daily. |
| DRUG | Temodar | Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle. |
Timeline
- Start date
- 2003-01-01
- Primary completion
- 2011-03-09
- Completion
- 2011-03-09
- First posted
- 2008-04-28
- Last updated
- 2023-03-30
- Results posted
- 2023-03-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00667953. Inclusion in this directory is not an endorsement.